{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:49:39Z","timestamp":1792554579176,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["205687"],"award-info":[{"award-number":["205687"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["NCT03085797"],"award-info":[{"award-number":["NCT03085797"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jaip.2023.08.015","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T21:08:48Z","timestamp":1692047328000},"page":"3504-3512.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps"],"prefix":"10.1016","volume":"11","author":[{"given":"Geoffrey","family":"Chupp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isam","family":"Alobid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha H.","family":"Kariyawasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Chaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana R.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhabita","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.08.015_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of chronic rhinosinusitis and nasal polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaip.2023.08.015_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.08.015_bib3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/0091-6749(93)90267-J","article-title":"Eosinophils in nasal polyps and nasal mucosa: an immunohistochemical study","volume":"91","author":"Stoop","year":"1993","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.08.015_bib4","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.08.015_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4193\/Rhin16.065","article-title":"Sleep quality improves with endoscopic sinus surgery in patients with chronic rhinosinusitis and nasal polyposis","volume":"55","author":"Varendh","year":"2017","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2023.08.015_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022644","article-title":"Chronic rhinosinusitis: a qualitative study of patient views and experiences of current management in primary and secondary care","volume":"9","author":"Vennik","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2023.08.015_bib7","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/lary.21847","article-title":"Health state utility values in patients undergoing endoscopic sinus surgery","volume":"121","author":"Soler","year":"2011","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2023.08.015_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2023.08.015_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1016705615207","article-title":"Functional status, health problems, age and comorbidity in primary care patients","volume":"10","author":"Wensing","year":"2001","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaip.2023.08.015_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2023.08.015_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0151-2019","article-title":"Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety","volume":"29","author":"Price","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2023.08.015_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4193\/Rhino15.367","article-title":"The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review","volume":"55","author":"Winblad","year":"2017","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2023.08.015_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2023.08.015_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2023.08.015_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13601-019-0303-6","article-title":"Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper","volume":"10","author":"Hox","year":"2020","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2023.08.015_bib16","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","article-title":"The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use","volume":"103","author":"Manson","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2023.08.015_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2023.08.015_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4193\/Rhin17.255","article-title":"The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2023.08.015_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13601-019-0269-4","article-title":"Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis","volume":"9","author":"Calus","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2023.08.015_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/000348941011900705","article-title":"Relationship between postoperative recurrence rate and eosinophil density of nasal polyps","volume":"119","author":"Tosun","year":"2010","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jaip.2023.08.015_bib21","first-page":"109","article-title":"Twelve-year long-term postoperative outcomes in patients with chronic rhinosinusitis with nasal polyps","volume":"60","author":"Arancibia","year":"2022","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2023.08.015_bib22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.08.015_bib23","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.08.015_bib24","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.08.015_bib25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2023.08.015_bib26","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.08.015_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/JAA.S40244","article-title":"Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases","volume":"8","author":"Menzella","year":"2015","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2023.08.015_bib28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.08.015_bib29","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.08.015_bib30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.08.015_bib31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.08.015_bib32","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.08.015_bib33","series-title":"Mepolizumab summary of product characteristics","year":"2020"},{"key":"10.1016\/j.jaip.2023.08.015_bib34","series-title":"Mepolizumab prescribing information","year":"2022"},{"key":"10.1016\/j.jaip.2023.08.015_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/pst.1909","article-title":"Strategies for composite estimands in confirmatory clinical trials: examples from trials in nasal polyps and steroid reduction","volume":"18","author":"Keene","year":"2019","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jaip.2023.08.015_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/pst.1817","article-title":"Missing data in clinical trials: control-based mean imputation and sensitivity analysis","volume":"16","author":"Mehrotra","year":"2017","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jaip.2023.08.015_bib38","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/coa.13177","article-title":"Minimal clinically important difference for the 22-item Sinonasal Outcome Test in medically managed patients with chronic rhinosinusitis","volume":"43","author":"Phillips","year":"2018","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.jaip.2023.08.015_bib39","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.08.015_bib40","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/coa.13177","article-title":"Minimal clinically important difference for the 22-item Sinonasal Outcome Test in medically managed patients with chronic rhinosinusitis","volume":"43","author":"Phillips","year":"2018","journal-title":"Clin Otolaryngol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823009182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823009182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:39:30Z","timestamp":1761975570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823009182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2213219823009182"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.08.015","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}